IRIS UniCatt

Borghetti, Alberto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.490
EU - Europa 3.963
AS - Asia 3.480
SA - Sud America 728
AF - Africa 126
OC - Oceania 30
Continente sconosciuto - Info sul continente non disponibili 6
AN - Antartide 1
Totale 12.824
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.312
SG - Singapore 1.612
IT - Italia 792
DE - Germania 762
CN - Cina 688
BR - Brasile 609
SE - Svezia 527
FR - Francia 442
NL - Olanda 377
VN - Vietnam 337
PL - Polonia 254
GB - Regno Unito 220
IE - Irlanda 153
IN - India 138
FI - Finlandia 124
CA - Canada 105
ID - Indonesia 102
JP - Giappone 102
HK - Hong Kong 80
UA - Ucraina 66
RU - Federazione Russa 62
BD - Bangladesh 61
AR - Argentina 47
TR - Turchia 47
MX - Messico 41
PK - Pakistan 40
IQ - Iraq 35
KR - Corea 34
AT - Austria 33
BE - Belgio 32
ZA - Sudafrica 31
SA - Arabia Saudita 29
ES - Italia 28
IR - Iran 28
AU - Australia 27
PH - Filippine 20
LT - Lituania 18
MA - Marocco 18
VE - Venezuela 18
CI - Costa d'Avorio 17
EG - Egitto 16
CH - Svizzera 14
EC - Ecuador 13
MY - Malesia 13
CO - Colombia 11
KE - Kenya 11
UZ - Uzbekistan 11
IL - Israele 10
PY - Paraguay 10
AE - Emirati Arabi Uniti 9
CZ - Repubblica Ceca 9
NP - Nepal 9
TN - Tunisia 9
CL - Cile 8
TW - Taiwan 8
AZ - Azerbaigian 7
JO - Giordania 7
NG - Nigeria 7
AL - Albania 6
BO - Bolivia 6
JM - Giamaica 6
MD - Moldavia 6
TH - Thailandia 6
GR - Grecia 5
KG - Kirghizistan 5
KZ - Kazakistan 5
LB - Libano 5
OM - Oman 5
PT - Portogallo 5
BH - Bahrain 4
CR - Costa Rica 4
DK - Danimarca 4
DO - Repubblica Dominicana 4
EU - Europa 4
PA - Panama 4
PE - Perù 4
RO - Romania 4
TT - Trinidad e Tobago 4
ET - Etiopia 3
HR - Croazia 3
MM - Myanmar 3
NO - Norvegia 3
NZ - Nuova Zelanda 3
PS - Palestinian Territory 3
QA - Qatar 3
SD - Sudan 3
BG - Bulgaria 2
BN - Brunei Darussalam 2
BY - Bielorussia 2
CM - Camerun 2
DZ - Algeria 2
GE - Georgia 2
GT - Guatemala 2
HN - Honduras 2
KW - Kuwait 2
LK - Sri Lanka 2
LU - Lussemburgo 2
MG - Madagascar 2
MO - Macao, regione amministrativa speciale della Cina 2
PR - Porto Rico 2
Totale 12.798
Salva come PNG Salva come JPEG
Città #
Singapore 904
Chandler 626
Ashburn 488
San Jose 402
Amsterdam 360
Kraków 209
New York 203
Milan 188
Rome 176
Dublin 150
Beijing 146
Los Angeles 128
Ho Chi Minh City 115
Dallas 112
The Dalles 107
Lauterbourg 97
Tokyo 97
Jakarta 93
Hefei 89
Hanoi 88
St Louis 85
San Mateo 79
Helsinki 72
Frankfurt am Main 69
Boston 67
Hong Kong 66
Jacksonville 61
São Paulo 61
Chicago 59
Munich 52
Ann Arbor 48
Princeton 48
Wilmington 48
Marseille 43
Council Bluffs 41
Santa Clara 39
London 38
Orem 37
Houston 36
Warsaw 35
Montreal 33
Redmond 33
Nanjing 32
Brooklyn 31
Moscow 30
Brussels 29
Buffalo 29
Nuremberg 29
Denver 28
Lancaster 27
Seoul 27
Cattolica 26
Paris 26
Kent 25
Toronto 25
Düsseldorf 24
Boardman 23
Vienna 23
Atlanta 21
Pune 21
Chennai 20
Dearborn 20
Manchester 20
Rio de Janeiro 20
Seattle 20
Fairfield 19
Haiphong 19
Turku 19
Poplar 18
Roubaix 18
Stockholm 18
Johannesburg 17
Lawrence 17
Abidjan 16
North Bergen 16
Woodbridge 16
Augusta 15
Lahore 15
Lappeenranta 15
Mexico City 15
Phoenix 15
Portsmouth 15
Belo Horizonte 14
Bremen 14
Dhaka 14
Dammam 13
Redwood City 13
Tianjin 13
Da Nang 12
Guangzhou 12
Norwalk 12
Washington 12
Izmir 11
Kish 11
Nürnberg 11
Shanghai 11
Bexley 10
Hangzhou 10
Mumbai 10
Ottawa 10
Totale 7.000
Salva come PNG Salva come JPEG
Nome #
Functional associations between polymorphic regions of the human 3'IgH locus and COVID-19 disease 796
Post-COVID-19 global health strategies: the need for an interdisciplinary approach 526
Asthma in patients admitted to emergency department for COVID-19: prevalence and risk of hospitalization 306
Fatigue in Covid-19 survivors: The potential impact of a nutritional supplement on muscle strength and function 230
Post-COVID-19 global health strategies: the need for an interdisciplinary approach 227
Prevalence of osteoporosis and predictors of low BMD in a cohort of HIV-1-infected patients in Rome: features of a population at high risk 218
Liver fibrosis is associated with cognitive impairment in HIV-positive patients 218
Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre 217
Fatigue in Covid-19 survivors: The potential impact of a nutritional supplement on muscle strength and function 208
Neuropsychological screening tools in Italian HIV+ patients: a comparison of Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE) 201
Retinal capillary involvement in early post-COVID-19 patients: a healthy controlled study 201
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2 years follow-up in HIV-infected patients 199
Residual respiratory impairment after COVID-19 pneumonia 190
Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients 189
Ophthalmic artery resistance index IS increased in HIV-Infected patients and is influenced by protease inhibitors exposure 186
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study 185
Residual respiratory impairment after COVID-19 pneumonia 168
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients 166
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) 166
Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial 165
Shall we dance? Extending tango's results to clinical practice 160
Psychological Distress After Covid-19 Recovery: Reciprocal Effects With Temperament and Emotional Dysregulation. An Exploratory Study of Patients Over 60 Years of Age Assessed in a Post-acute Care Service 160
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2-year follow-up in HIV-infected patients 158
The University of California San Diego performance-based skills assessment: a useful tool to detect mild everyday functioning difficulties in HIV-infected patients with very good immunological condition 157
Lung ultrasonography for early management of patients with respiratory symptoms during COVID-19 pandemic 157
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy 154
Cardiovascular Disease Risk in a Cohort of Virologically Suppressed People Living with HIV Switching to Doravirine: Preliminary Data from the Real Life 147
Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study 147
Are we ready for long-acting? A feasibility evaluation of long-acting cabotegravir–rilpivirine in clinical practice 147
Treatment of Aorto-iliac and Infrainguinal Vascular Infections with a Prefabricated Bovine Pericardial Graft 146
HIV-Related Internalized Stigma and Patient Health Engagement Model in an Italian Cohort of People Living With HIV 146
Difference in the neurocognitive functions of WLWH and MLWH in an Italian cohort of people living with HIV 146
Psychological distress during the initial stage of the COVID-19 pandemic in an italian population living with HIV: An online survey 138
The University of California San Diego performance-based skills assessment: a useful tool to detect mild everyday functioning difficulties in HIV-infected patients with very good immunological condition 136
Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line 129
Impact of the COVID-19 Pandemic on Health Care Is Negatively Associated With Psychosocial Well-Being in an Italian Cohort of People Living With HIV 129
Seroprevalence of sars-cov-2 antibodies in hiv-infected patients in rome, italy during the covid-19 outbreak 126
Short Communication: Comparing Lamivudine+Dolutegravir and Bictegravir/Emtricitabine/Tenofovir Alafenamide as Switch Strategies: Preliminary Results from Clinical Practice 120
HIV and vicarious stigma in a cohort of people living with HIV in Italy: What happens when the stigma is fueled by healthcare providers? 117
SARS-CoV-2 infection in a highly experienced person living with HIV 117
Fatigue in Covid-19 survivors: The potential impact of a nutritional supplement on muscle strength and function 116
Prevalence, incidence and predictors of anal high-risk HPV infections and cytological abnormalities in HIV-infected individuals 116
Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients 116
Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort 116
Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study 115
Use of telehealth for HIV care in Italy: Are doctors and patients on the same page? A cross-sectional study 114
Early use of tecovirimat in a young man with severe mpox skin lesions: a case report 113
Use of Long-Acting Therapies for HIV Care in Italy: Are People Living with HIV Prepared for Change? A Cross-Sectional Study 112
The association between stigma and wellbeing in an Italian cohort of PLWH: The role of social support and personal factors 111
Atypical ductal hyperplasia on vacuum-assisted breast biopsy: a scoring system to predict the risk of upgrade to malignancy 111
Blood telomere length gain in people living with HIV switching to dolutegravir plus lamivudine versus continuing triple regimen: a longitudinal, prospective, matched, controlled study 109
Derivation and validation of a scoring system to assess pre-test probability of being COVID-19 positive 108
Risk of Tumor Onset in HIV+ Patients on Two-Drug Regimens: A Cohort Study in an Italian Hospital 108
Changes in Metabolic Profile in PLWHIV Switching to Doravirine-Based Regimen 107
Differences in the Long-term Impact of the COVID-19 Pandemic on the Mental Health and Professional Quality of Life of Resident and Specialist Physicians 106
Efficacy of Lamivudine Plus Dolutegravir vs Dolutegravir-Based 3-Drug Regimens in People With HIV Who Are Virologically Suppressed 105
Letter to the Editor: Real-Life Experience of Long-Acting Cabotegravir-Rilpivirine Combination in a Person Living with HIV with Detectable Viremia: A Case Report 104
Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy 103
Comparing the long-term effectiveness and safety of dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide fumarate as first-line regimens: A real life multicentre cohort 101
The need to continue testing for HIV, even during the coronavirus disease 2019 (COVID-19) pandemic 101
Integrase Inhibitors Use and Cytomegalovirus Infection Predict Immune Recovery in People Living With HIV Starting First-Line Therapy 100
Comparative safety review of recommended, first-line single-tablet regimens in patients with HIV 98
Characteristics of mental health interventions in a cohort of Italian PLWH over the last five years: impact of HIV disease and outbreak of COVID-19 pandemic 97
People Living with HIV in the COVID-19 Era: A Case Report 97
Implementing a Personalized Antimicrobial Stewardship Program for Women with Gynecological Cancers and Healthcare-Associated Infections 97
Clinical presentation of human monkeypox virus infection during the 2022 outbreak: descriptive case series from a large italian Research Hospital 97
Virological outcomes with dolutegravir plus either lamivudine or two NRTIs as switch strategies: a multi-cohort study 96
Dolutegravir Discontinuation for Neuropsychiatric Symptoms in People Living with HIV and Their Outcomes after Treatment Change: A Pharmacogenetic Study 95
Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients 95
Determinants of SARS-COV-2 seroconversion in a cohort of recovered patients 94
New insight of human-IgH 3′regulatory regions in immunoglobulins switch 93
COVID-19 diagnosis does not rule out other concomitant diseases 93
Inflammation markers in virologically suppressed HIV-Infected patients after switching to dolutegravir plus lamivudine vs continuing triple therapy: 48-week results in real-life setting 92
No evidence of SARS-CoV-2 circulation in HIV-infected patients between December 2019 and February 2020 in Rome, Italy 92
Real World Data from an Italian Outpatient Clinical Setting and from Home Care Assistance of Treatment-Experienced PWH Switching to CAB + RPV Regimen: A Prospective Observational Study 91
Off-label use of tocilizumab in patients with SARS-CoV-2 infection 91
Transmitted drug resistance to NRTIs and risk of virological failure in naïve patients treated with integrase inhibitors 91
People Living with HIV in the COVID-19 Era: A Case Report 90
Derivation and validation of a scoring system to assess pre-test probability of being COVID-19 positive 89
Nasopharingeal bacterial and fungal colonization in HIV-positive versus HIV-negative adults 87
Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients during Lamivudine plus Dolutegravir Maintenance Therapy in Clinical Practice 82
Short Communication: Efficacy and Safety of Dolutegravir plus Lamivudine as a First-Line Regimen in Clinical Practice 82
Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: A multicenter retrospective cohort study from 2007 to 2015 82
Focal status epilepticus as unique clinical feature of COVID-19: A case report 79
Still much to learn about the diagnostic role of SARS-CoV-2 antibody detection 76
Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study 74
Older Age is Associated with Higher Dolutegravir Exposure in Plasma and Cerebrospinal Fluid of People Living with HIV 72
Kaposi-like manifestations in a newly diagnosed aids transgendered patient with silicone embolism syndrome and disseminated tuberculosis 72
No significant changes in body fat mass in virologically suppressed, HIV-positive patients switched to lamivudine-Dolutegravir 71
Real-life findings on the impact of the COVID-19 pandemic on HIV care 71
Assessing dengue seroprevalence among people living with HIV (PLWH) in rome, Italy: Insights from the 2023 Italian autochthonous outbreak 69
Lung ultrasonography for early management of patients with respiratory symptoms during COVID-19 pandemic 64
The need to continue testing for HIV, even during the coronavirus disease 2019 (COVID-19) pandemic 63
Comparison of HIV-DNA decay in naive patients starting dolutegravir plus lamivudine or dolutegravir-based triple therapy 63
Evolution of cellular HIV DNA levels in virologically suppressed patients switching to dolutegravir/lamivudine versus maintaining a triple regimen: a prospective, longitudinal, matched, controlled study 58
Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients 58
Totale 13.002
Salva come PNG Salva come JPEG
Categoria #
all - tutte 52.372
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 52.372
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202198 0 0 0 0 0 0 0 0 0 36 48 14
2021/2022714 35 21 16 74 20 23 65 116 31 56 89 168
2022/20232.059 212 261 180 330 209 273 85 156 220 54 60 19
2023/20241.121 43 227 36 100 62 183 77 30 39 54 136 134
2024/20252.263 29 54 262 87 176 93 147 115 300 187 469 344
2025/20265.645 733 175 353 712 988 931 821 267 304 361 0 0
Totale 13.002